Henan Lingrui Pharmaceutical Co (SHSE:600285) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600285 Henan Lingrui Pharmaceutical Co Ltd SHSE:600285
84 GF Score
Price ¥19.13
GF Value ¥23.88
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Henan Lingrui Pharmaceutical Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Henan Lingrui Pharmaceutical Co  (SHSE:600285) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Henan Lingrui Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms


Henan Lingrui Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Henan Lingrui Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Henan Lingrui Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Henan Lingrui Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.39 3.88 4.54 5.26 4.42

Henan Lingrui Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.02 4.72 4.36 4.56 3.87

SHSE:600285 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Henan Lingrui Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Henan Lingrui Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Henan Lingrui Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Henan Lingrui Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600285
84GF Score
Henan Lingrui Pharmaceutical Co Ltd SHSE:600285
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Henan Lingrui Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Henan Lingrui Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Henan Lingrui Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.802/116.0564*116.0564
=1.802

Current CPI (Jun. 2026) = 116.0564.

Henan Lingrui Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.647 102.400 0.733
201612 0.663 102.600 0.750
201703 0.700 103.200 0.787
201706 0.706 103.100 0.795
201709 0.797 104.100 0.889
201712 0.918 104.500 1.020
201803 0.939 105.300 1.035
201806 0.925 104.900 1.023
201809 0.837 106.600 0.911
201812 0.788 106.500 0.859
201903 1.001 107.700 1.079
201906 1.016 107.700 1.095
201909 0.920 109.800 0.972
201912 0.821 111.200 0.857
202003 0.854 112.300 0.883
202006 1.204 110.400 1.266
202009 1.012 111.700 1.051
202012 1.025 111.500 1.067
202103 1.043 112.662 1.074
202106 1.338 111.769 1.389
202109 1.235 112.215 1.277
202112 1.156 113.108 1.186
202203 1.224 114.335 1.242
202206 1.490 114.558 1.509
202209 1.256 115.339 1.264
202212 1.303 115.116 1.314
202303 1.389 115.116 1.400
202306 1.600 114.558 1.621
202309 1.437 115.339 1.446
202312 1.421 114.781 1.437
202403 1.581 115.227 1.592
202406 1.755 114.781 1.775
202409 1.504 115.785 1.508
202412 1.291 114.893 1.304
202503 1.800 115.116 1.815
202506 1.902 114.907 1.921
202509 1.660 115.471 1.668
202512 1.436 115.832 1.439
202603 1.986 116.303 1.982
202606 1.802 116.056 1.802

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Henan Lingrui Pharmaceutical Co (SHSE:600285) Overvalued in 2026?

Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥19.13 is trading 19.9% below its estimated GF Value™ of ¥23.88. GuruFocus considers Henan Lingrui Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600285:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: ¥23.88 vs. price of ¥19.13 (19.9% below fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600285 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Henan Lingrui Pharmaceutical Co Business Description

Address No. 59 Jiefang Chengguan Road, Xinxian, Xinyang, Henan, CHN, 465550
Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.
84GF Score

Get the complete analysis for SHSE:600285

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥19.13
Price
¥23.88
GF Value